

VGI Health Technology updates Sunset Date on sale of Subsidiary Invictus BioPharma Pty Ltd

Sydney New South Wales, 8 September 2022 – VGI Health Technology Limited (NSX:VTL) has previously announced on 5 April 2022 that a binding agreement for the sale of its wholly-owned subsidiary Invictus BioPharma Pty Ltd (IBP) had been executed with Invictus BioPharma Holdings Ltd (IVBHL) (the **Transaction**). The transaction was approved by VTL's shareholders on 3 June 2022.

To enable completion VTL and IVBHL have agreed to amend the sunset date of the transaction to 31 October 2022.

This announcement was authorised for release by the board of VGI Health Technology Limited.

For more information please contact:

Glenn Tong, CEO and Managing Director
Ph: +61 (0) 412 193 350

Steven Yu, Director
Ph: +61 (0) 408 898 656

About VGI Health Technology Limited

VGI Health Technology Limited trading as VGI Health Technology is an Australian public listed biotechnology company (NSX:VTL) developing and commercialising novel dietary supplements and prescription medicines based on natural products (tocotrienols) which have wide therapeutic potential, including: Delayed Onset Muscle Soreness, muscle recovery, exercise endurance, Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic SteatoHepatitis (NASH), pancreatic cancer, hyperlipidaemia, hypertension and diabetes. VTL owns and controls patent and other intellectual property rights for novel approaches to non-invasively delivering tocotrienols directly to the target tissues. The Company has a product development program for evidence-based nutraceuticals and a clinical development program for prescription medicines.

For more information see: <https://www.vgiht.com>

Investors interested in trading shares on the NSX should contact a broker who is an NSX Participant:
https://www.nsx.com.au/broker_list_print.asp